Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of pneumococcal vaccination after prime boosting in HIV-infected adults
2011-000260-99Phase 3Completed
- Sponsor
- Department of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8
- Start
- Feb 2011
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of pneumococcal 13-valent conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Department of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8. Primary endpoint: Primary immunogenicity endpoint at week 8. Started Feb 2011; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2011-000260-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000260-99.